Pisa Syndrome Seen with Donepezil/Adverse Reaction Due to Wrong Route of Administration/Pediatric Drug-Induced Hypersensitivity Syndrome/Burning Mouth Syndrome with Clonazepam/Bone Marrow Failure Due to Methotrexate Given in Error/Nevirapine Therapy and DRESS Syndrome

2001 ◽  
Vol 36 (10) ◽  
pp. 1036-1042 ◽  
Author(s):  
Joel Shuster
Keyword(s):  
Bone Marrow ◽  
Adverse Reaction ◽  
Bone Marrow Failure ◽  
Hypersensitivity Syndrome ◽  
Burning Mouth Syndrome ◽  
Dress Syndrome ◽  
Pediatric Drug ◽  
Drug Induced ◽  
Pisa Syndrome ◽  
Burning Mouth

Burning Mouth Syndrome: Problem in the Mouth?

2017 ◽  
Vol 41 (S1) ◽  
pp. S254-S254
Author(s):  
S. Petrykiv ◽  
L. de Jonge ◽  
M. Arts
Keyword(s):  
Case Report ◽  
Case Reports ◽  
Antidepressant Medication ◽  
Burning Mouth Syndrome ◽  
Psychiatric Ward ◽  
Drug Induced ◽  
First Case ◽  
Painful Sensation ◽  
Burning Mouth ◽  
Competing Interest

IntroductionBurning mouth syndrome (BMS) is characterized by an intraoral burning sensation for which no medical or dental cause can be found. Sporadic evidence suggests that drug induced conditions may evoke BMS. Intriguingly, we observed a patient who developed BMS after induction of citalopram.Objectives & aimsA case report of patient with BMS from our psychiatric ward will be presented here, followed by a literature review on drugs induced BMS.MethodsBased on a recent literature search, we present a first case report of BMS that was apparently induced in patient shortly after beginning of citalopram. We performed a systematic search through PubMed, EMBASE and Cochrane's Library to find more cases of psychotropic induced BMS.ResultsMs. A. was a 72-year old woman meeting DSM-IV diagnostic criteria for melancholic depression, who was observed in a clinical setting. We started citalopram 10 mg. 1dd1, with 10 mg. 1dd1 increase over 7 days to 20 mg, 1dd1. The following day, she displayed a persistent burning painful sensation in the mouth. Other than BMS oropharyngological syndromes were excluded after consultation with qualified medical specialists. Citalopram therapy was discontinued, and nortrilen treatment was initiated. BMS symptoms resolved over four days. Twelve case reports have linked BMS to the use antidepressants and anxiolytics.ConclusionContrasting the statement that no medical cause can be found for BMS, we found that psychotropics may evoke the syndrome. Compared to other psychotropic drugs, antidepressant medication has the strongest association with BMS.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals How I treat warm autoimmune hemolytic anemia

Blood ◽  
2021 ◽  
Author(s):  
Wilma Barcellini ◽  
Bruno Fattizzo
Keyword(s):  
Bone Marrow ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Bone Marrow Failure ◽  
Clinical Severity ◽  
Therapeutic Interventions ◽  
Drug Induced ◽  
Bone Marrow Failure Syndromes ◽  
Dependent Cell ◽  
Changes Over Time

Warm autoimmune hemolytic anemia (wAIHA) is caused by increased erythrocyte destruction by IgG autoantibodies, with or without complement activation. Antibody-dependent cell-mediated cytotoxicity by macrophages/activated lymphocytes occurs in the lymphoid organs and spleen (extravascular hemolysis). The ability of the bone marrow to compensate determines clinical severity. The different pathogenic mechanisms, their complex interplay, and changes over time may explain wAIHA's great clinical heterogeneity and unpredictable course. The disease may be primary, drug-induced, or associated with lymphoproliferative neoplasms, autoimmune and infectious diseases, immunodeficiencies, solid tumors, or transplants. Therapeutic interventions include steroids, splenectomy, immunosuppressants, and rituximab; the latter is increasingly used in steroid refractory cases based on evidence from the literature and a few prospective trials. We present five patient case studies highlighting important issues: 1) the diagnosis and proper use of steroid therapy; 2) the concerns about the choice between rituximab and splenectomy in second-line treatment; 3) the need of periodical re-evaluation of the disease to assess the possible evolution of relapsed/refractory cases in myelodysplastic and bone marrow failure syndromes; and 4) the difficulties in managing cases of severe/acute disease which are at high risk of relapse. Incorporating novel targeted therapies into clinical practice will be an exciting challenge in the future.

scholarly journals Lamotrigine Associated DRESS Syndrome – a Case Report

2015 ◽  
Vol 7 (1) ◽  
pp. 23-33 ◽  
Author(s):  
Jagoda Balaban ◽  
Đuka Ninković-Baroš
Keyword(s):  
Case Report ◽  
Female Patient ◽  
Skin Rash ◽  
Respiratory Symptoms ◽  
Hypersensitivity Syndrome ◽  
Organ Involvement ◽  
Dress Syndrome ◽  
Drug Induced ◽  
Drug Rash ◽  
Systemic Symptoms

AbstractDrug-induced delayed multiorgan hypersensitivity syndrome, also known as drug rash (reaction) with eosinophilia and systemic symptoms (DRESS) syndrome, represents a drug-induced cluster of skin, hematologic and systemic symptoms. More than forty drugs have been associated with this syndrome. We present a case of DRESS syndrome suspecting that lamotrigine was directly responsible for the patient’s rash and other symptoms. A female patient presented with extensive skin rash, fever, hematologic abnormalities, organ involvement such as hepatitis, pancreatitis and respiratory symptoms. The symptoms developed four weeks after the initiation of the offending drug, and disappeared eight weeks after its discontinuation.

scholarly journals Anticonvulsant hypersensitivity syndrome: clinic case and literature review

2020 ◽  
Vol 77 (3) ◽  
pp. 211-213 ◽  
Author(s):  
Sebastian Leonangeli ◽  
Jazmín Azul Fraire ◽  
Jorge Luis Loza
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Literature Review ◽  
Hypersensitivity Reaction ◽  
Hypersensitivity Syndrome ◽  
Severe Reaction ◽  
Dress Syndrome ◽  
Internal Organs ◽  
Anticonvulsant Hypersensitivity Syndrome ◽  
Strong Medicine

Introduction: The anticonvulsant hypersensitivity syndrome is a rare adverse reaction in which the skin, lymph nodes and internal organs are affected. It is usually caused by classic anticonvulsants such as phenytoin, carbamazepine or phenobarbital. Case report: Here we present the case of a 25-year-old woman from Córdoba, Argentina, who suffered a severe reaction to oxcarbazepine with a rash, lymphadenopathy, hepatitis and an unusual analytic. Clinical abnormalities were reversed after oxcarbazepine was terminated and treatment with diphenhydramine and dexamethasone was initiated. Discussion: DRESS syndrome is a hypersensitivity reaction that takes weeks to manifest, and is characterized by rash, leukocytosis with eosinophilia, adenopathies, liver involvement, and reactivation of the herpes virus 6, being more frequent in carbamazepine or phenytoin, and in rare cases to oxcarbazepine. Conclusions: In general, this strong medicine is not taken into account as a cause of hypersensitivity, reports suggest that it could be related to cases similar to this one, and studies that are more targeted are required, due to the morbidity and mortality of the syndrome.

Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy

2021 ◽  
pp. 107815522110625
Author(s):  
Austin Ambur ◽  
Lindsay Ambur ◽  
Leila Khan ◽  
Rajiv Nathoo
Keyword(s):  
Glioblastoma Multiforme ◽  
Hypersensitivity Syndrome ◽  
Stevens Johnson Syndrome ◽  
Dress Syndrome ◽  
Drug Induced ◽  
Johnson Syndrome ◽  
Alternative Treatment Option ◽  
Desensitization Therapy ◽  
Cutaneous Hypersensitivity ◽  
Life Threatening

Introduction Temozolomide is an oral alkylating agent used as first line treatment of glioblastoma multiforme (GBM). It has also been used in the treatment of certain solid tumors such as metastatic melanoma. Commonly reported adverse effects include nausea and vomiting, constipation, headache, fatigue and myelosuppression. Cutaneous hypersensitivity reactions are rare and include an urticarial hypersensitivity reaction, alopecia, and Stevens–Johnson syndrome. To our knowledge, there are minimal reports of temozolomide-induced DRESS syndrome. Case Report We present a 54-year-old man with glioblastoma multiforme who presented with a fever, diarrhea and progressively worsening rash 6 weeks after starting temozolomide. Management & Outcome The patient was diagnosed recurrent DRESS syndrome and restarted on a gradual prednisone taper with resolution over the following weeks. Unfortunately, the patient was unable to be followed long-term due to relocation to a different state. Discussion To our knowledge, there are minimal reports of temozolomide-induced DRESS syndrome. The diagnosis can be life-threatening, which makes management of patients with GBM and no alternative treatment option challenging. The use of de-sensitization therapy to temozolomide has been proposed for the management of severe adverse cutaneous reactions.

scholarly journals ATT-Therapy Induced DRESS: A Case Report

2021 ◽  
Vol 11 (5-S) ◽  
pp. 1-5
Author(s):  
Navya Sri G ◽  
Feba Stanly ◽  
Georgina Sarah ◽  
Prasad Bali ◽  
Varsha Dalal
Keyword(s):  
Drug Reaction ◽  
Clinical Symptoms ◽  
Latency Period ◽  
Hypersensitivity Syndrome ◽  
The Body ◽  
Dress Syndrome ◽  
Tubercular Meningitis ◽  
Drug Induced ◽  
Systemic Symptoms ◽  
Anti Tubercular Therapy

A severe adverse reaction called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome), is usually described by eosinophilia, fever, swollen lymph nodes, severe skin rash and extensive systemic association. It is distinguished by a lengthy latency period, which is characteristic drug reaction with eosinophilia and systemic symptoms (DRESS). Formerly known as drug-induced delayed multi-organ hypersensitivity syndrome (DIDMOHS) or drug-induced hypersensitivity (DIHS). There are a variety of clinical symptoms associated with the syndrome yet it is still poorly understood. Drugs most commonly implicate in Anticonvulsants are the most common cause of DRESS syndrome, followed by sulfonamides and a variety of anti-inflammatory medications.Anti-tubercular therapy (ATT) is rarely associated with DRESS syndromeWe present the case of a 60-year-old female patient who had previously been treated with Anti-tubercular Therapy for Tubercular Meningitis (ATT).She was admitted to the hospital with presenting complaints of vomiting, burning micturition, fever associated with chills, generalized swelling and reddish skin all over the body including facial puffiness. The problem was successfully resolved by refraining from the offending medication and administering supportive care. Thus, the case illustrates the necessity of considering anti-tubercular drug reactions even when symptoms are delayed. Keywords: Anti-tubercular Therapy (ATT), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Adverse drug reaction (ADR), Drug-induced, Systemic symptoms syndrome,

Sign in / Sign up

Export Citation Format

Share Document